These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 21497066)

  • 41. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
    Efe S; Sinirtaş M; Ozakin C
    Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
    Mendes RE; Sader HS; Jones RN
    Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
    Wagenlehner FM; Lehn N; Witte W; Naber KG
    Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
    Allen GP; Bierman BC
    Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.
    Hawser SP; Bouchillon SK; Hoban DJ; Dowzicky M; Babinchak T
    Int J Antimicrob Agents; 2011 Mar; 37(3):219-24. PubMed ID: 21239146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.
    Pankey GA; Ashcraft DS
    Diagn Microbiol Infect Dis; 2009 Jul; 64(3):300-4. PubMed ID: 19501791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
    Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):206-13. PubMed ID: 23478031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.
    Draghi DC; Sheehan DJ; Hogan P; Sahm DF
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5024-32. PubMed ID: 16304168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial susceptibility among bacterial isolates from ICU and non-ICU setting and different age groups: results from the tigecycline evaluation and Surveillance trial in North America.
    Low DE; Markovic MJ; Dowzicky MJ
    J Chemother; 2009 Feb; 21(1):16-23. PubMed ID: 19297267
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
    Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
    Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H; Dowzicky MJ
    Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activities of tigecycline against clinical isolates from Shanghai, China.
    Zhang YY; Zhou L; Zhu DM; Wu PC; Hu FP; Wu WH; Wang F
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):267-81. PubMed ID: 15582300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Steckelberg JM
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
    J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries.
    Ko KS; Song JH; Lee MY; Park S; Kwon KT; Heo ST; Ryu SY; Oh WS; Peck KR; Lee NY
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):337-41. PubMed ID: 16631337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.